4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - EST)

22nd - 23rd April, 2021

EVENT OVERVIEW

MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April, 2021.

While the 3rd annual virtual conference had discussions on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19.

Our aim for the 4th Annual Virtual Conference is to unite all stakeholders in a virtual room to learn how to overcome the challenges caused due to the pandemic, efficiently and effectively generating RWE for stakeholders including payers, patients and physicians.

WHAT TO EXPECT

  

  • Real-world data- Demonstrating value for all stakeholders
  • Managing the big data available including the COVID data
  • Relation between real-world evidence and clinical development
  • Real-world evidence supporting patient access
  • Importance of PRO
  • Attaining uniformity in data in all clinical parameters for better comparison

  

  • Learn about the recent trends and advancements in Real-World Evidence Generation
  • Engage in meaningful discussion with the most prominent industry experts and decision makers from pharmaceutical and biopharmaceutical companies who will address most critical challenges in real-world data and real-world evidence space.
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading pharmaceutical companies, global regulators, and solution providers

  • From Pharmaceutical and Biopharmaceutical companies

    Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologists, within the following departments-

  • Real-World Evidence
  • Health Economics & Outcomes Research
  • Market Access
  • Value Access
  • Clinical Outcomes
  • Clinical Development
  • Center for Observational and Real-World Evidence  

CONFERENCE AGENDA

Registration

 08:20 - 08:50

Welcome note from MarketsandMarkets

 08:50 - 08:55

Opening Remarks from the Chairman

Luis Prieto

Luis Prieto, Director Real World Evidence - Global Medical Affairs, Immunology, Hepatology & Dermatology, Novartis

 08:55 - 09:00

REAL-WORLD DATA- DEMONSTRATING VALUE FOR ALL STAKEHOLDERS

Keynote Presentation: Defining the Value in Value-based Contracting

Charles Makin

Charles Makin , Head of RWE, Boehringer-Ingelheim

 09:00 - 09:30

Harnessing the Power of Real-world Data and AI-driven Software to Accelerate Clinical Development

Usha Periyanayagam

Usha Periyanayagam, Head of Clinical Product and RWE, Komodo Health

 09:30 - 10:00

The Generating Evidence in Oncology (GEO) Initiative: A Payer, Provider, & Pharma Partnership

Brian Sweet

Brian Sweet , Executive Director, Oncology, Real World Evidence , Bristol-Myers Squibb

 10:00 - 10:30

Use of natural history control data to demonstrate treatment effect and optimise access to new therapies in DMD

Joel Iff

Joel Iff, Senior Director Global Market Access, Sarepta Therapeutics, USA

 10:30 - 11:00

One-to-One Networking Meetings | Networking break- virtual networking lounge

 11:00 - 11:20

IS BIG DATA NOW MORE IMPORTANT THAN MACHINE LEARNING!

Is data mining enough to extract meaningful healthcare-related evidence from Big Data or Machine Learning?

Luis Prieto

Luis Prieto, Director Real World Evidence - Global Medical Affairs, Immunology, Hepatology & Dermatology, Novartis

 11:20 - 11:50

AI-driven clinical data platforms - technology platforms to enable clinical outcome & RWE collaborations between Hospitals and Life Sciences Industry

Georges De Feu

Georges De Feu, Founder & CEO, Lynxcare

 11:50 - 12:20

Patients as partners in real-world evidence generation

Eliza Kruger

Eliza Kruger, Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

 12:20 - 12:50

Closing remarks from the Chairperson

 12:50 - 12:55

One-to-One Networking Meetings | Networking break- virtual networking lounge

 12:55 - 12:55

Registration

 08:40 - 09:20

Welcome note from MarketsandMarkets

 09:20 - 09:25

Opening Remarks from the Chairman

Tao Fan

Tao Fan , Senior Director, US HEOR US Medical Office , Takeda Pharmaceuticals

 09:25 - 09:30

REAL-WORLD EVIDENCE AND CLINICAL DEVELOPMENT - DO THEY NEED EACH OTHER!

RWE for demonstrating drug effectiveness

Nirosha Mahendraratnam Lederer

Nirosha Mahendraratnam Lederer, ,

09:30 - 09:50

Panel Discussion- Understanding scope of real-world evidence and how it compliments clinical trails

 09:50 - 10:40

One-to-One Networking Meetings | Networking break- virtual networking lounge

 10:40 - 11:00

REAL-WORLD EVIDENCE- A KEY FACTOR IN AIDING PATIENT ACCESS

Critical COVID-19 Questions – RWE Perspectives on the What, the Why and the How to Intervene

Myla Maloney

Myla Maloney, Vice President, Strategy and Commercial Operations, Premier Applied Sciences

 11:00 - 11:30

Patient Centricity beyond RCTs

Denise Globe

Denise Globe, Head of the HEOR COE, Gilead, USA

 11:30 - 12:00

Using real world data to support market access of rare disease indications

Lorenzo Sabatelli

Lorenzo Sabatelli, Health Evidence and Innovation Leader, Incyte

 12:00 - 12:30

Closing remarks from the Chairperson

 12:30 - 12:35

One-to-One Networking Meetings | Networking break- virtual networking lounge

 12:35 - 12:35

End of Conference

 12:35 - 12:35

CONFERENCE SPEAKERS

ADVISORS

Charles Makin

Charles Makin

Head of RWE, Boehringer-Ingelheim

Luis Prieto

Luis Prieto

Director Real World Evidence - Global Medical Affairs, Immunology, Hepatology & Dermatology, Novartis

Eliza Kruger

Eliza Kruger

Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

SPEAKERS

Charles Makin

Charles Makin

Head of RWE, Boehringer-Ingelheim

Lucy Pan

Lucy Pan

Director and Strategy Lead, Global Evidence & Value Development, EMD Serono

Nirosha Mahendraratnam Lederer

Nirosha Mahendraratnam Lederer

,

Georges De Feu

Georges De Feu

Founder & CEO, Lynxcare

Nneka Onwudiwe

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

Myla Maloney

Myla Maloney

Vice President, Strategy and Commercial Operations, Premier Applied Sciences

Usha Periyanayagam

Usha Periyanayagam

Head of Clinical Product and RWE, Komodo Health

Tao Fan

Tao Fan

Senior Director, US HEOR US Medical Office , Takeda Pharmaceuticals

Tanja Heidbrede

Tanja Heidbrede

Real-World Evidence Head, UCB, Europe

Luis Prieto

Luis Prieto

Director Real World Evidence - Global Medical Affairs, Immunology, Hepatology & Dermatology, Novartis

Brian Sweet

Brian Sweet

Executive Director, Oncology, Real World Evidence , Bristol-Myers Squibb

Eliza Kruger

Eliza Kruger

Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

Denise Globe

Denise Globe

Head of the HEOR COE, Gilead, USA

Lorenzo Sabatelli

Lorenzo Sabatelli

Health Evidence and Innovation Leader, Incyte

Joel Iff

Joel Iff

Senior Director Global Market Access, Sarepta Therapeutics, USA

SPONSORS

Komodo Health
Picnic Health
Adelphi Real World
Premier Inc.
RTI Health Solutions
Aetion
LynxCare

PARTNERS

PharmaVOICE
PharmaTutor
Pharma Journalist

24/7 Customer Support

Asia Office

Phone : +91 20 48598285
[email protected]

USA Office

Phone : +1-888600-6441
[email protected]